Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 355.89M P/E - EPS this Y 22.60% Ern Qtrly Grth -
Income -27.88M Forward P/E - EPS next Y -79.60% 50D Avg Chg 1.00%
Sales 2M PEG - EPS past 5Y - 200D Avg Chg 1.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -3.00%
Recommedations 1.80 Quick Ratio 16.78 Shares Outstanding 30.39M 52W Low Chg 9.00%
Insider Own 13.48% ROA -29.62% Shares Float 17.59M Beta -
Inst Own 48.52% ROE -46.96% Shares Shorted/Prior 2.07M/1.79M Price 16.05
Gross Margin 100.00% Profit Margin - Avg. Volume 89,276 Target Price 42.00
Oper. Margin -1,537.00% Earnings Date - Volume 57,395 Change 0.25%
About Sagimet Biosciences Inc. - Seri

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Sagimet Biosciences Inc. - Seri News
04/22/24 Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
03/27/24 Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
03/25/24 Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
03/25/24 Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
02/29/24 Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
01/25/24 Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
01/23/24 Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
01/22/24 Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
12/04/23 Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic
08:00 AM Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit
11/22/23 Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
11/13/23 Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
11/10/23 Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023
10/24/23 Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023
10/18/23 Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference
09/27/23 Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
08/29/23 ‘Load Up,’ Says Goldman Sachs About These 2 ‘Strong Buy’ Stocks
08/21/23 Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
08/15/23 Sagimet Biosciences Announces Closing of Underwriters’ Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering
07/20/23 Sagimet Biosciences Announces Leadership Changes
SGMT Chatroom

User Image harrigme Posted - 53 minutes ago

$SGMT pretty good article here: https://seekingalpha.com/article/4686709-sagimet-biosciences-denifanstat-phase-3-a-promising-opportunity

User Image WallStreetBuyDip Posted - 2 days ago

Will trade SGMT the as I did for other tickers. Look at the Step-By-Step showing how all were done for other tickers. Will buy when I get a confirmation for $SGMT This is how I get a reversal trade 95%+ of the times while many buy random levels. This shows the results from only setting a buy when H% is low. The results speak for themselves.

User Image John___wick44 Posted - 2 days ago

$SGMT bond but not jimmy is just a pumping clown. stock is done and to say otherwise is pure hype. 12-4 in last few months going bsck to 2. years behind players in industry. this play is years away.

User Image John___wick44 Posted - 2 days ago

$SGMT rates going higher stagflation. stock going to 2,peeps. dont buy when u can biy 50 percent cheaper

User Image BondbutnotJames Posted - 2 days ago

$SGMT even if it may read a bit unprincipled - the date May 3, 2024 does not seem to change anything - and that is a good thing - even if the event concerning Dr. Stephen Harrison is of course a tragic loss. Nevertheless, the course of events will take its course - let the facts we learn speak for themselves.

User Image John___wick44 Posted - 3 days ago

$SGMT rates going over 5 economy slowing infkation sticky. $2 stock

User Image Expharmaguy Posted - 3 days ago

$SGMT Some may not have heard, but Dr. Stephen Harrison, the KOL who was going to lead SGMT upcoming Webcast on May 3 passed away; he was the lead P.I. for MDGL's trials, and also the lead P.I. in GALT's important trial in compensated cirrhosis.

User Image maxhappy Posted - 3 days ago

$SGMT I predict this is the bottom for SGMT and it's heading much higher. The lockup expiry for their $12.50 secondary is tomorrow, and these things usually go up in situations like this after being whacked so hard. It's trading way below cash, and they will tell a good story at their investor day late next week on May 3. The risk/reward is fantastic.

User Image Expharmaguy Posted - 4 days ago

$SGMT I am accumulating in SGMT. Thesis: MOA of drug is among the most compelling vs. other MASH drug candidates, addressing all 3 drivers of liver progression; Drug is oral, and can be given once a day. (Convenience matters, especially when duration of treatment may be 12-18 mos). Combination treatment is where the MASH field is evolving to, and this drug is an ideal candidate to combine with Resmetirom, recently conditionally approved for F2/F3 fibrosis. Supporting potential for combination will be a poster for these 2 drugs at the EASL meeting; Underscoring this is the fact that Baker Brothers are invested in SGMT, and are the majority shareholders in MDGL which promotes Resmetirom.I Learned about SGMT from a publication by Dr. Scott Friedman. Dr. Friedman is the world's leading key opinion leader in MASH(formerly NASH). SGMT will initiate their phase 3 trial sometime later this year, but now that MDGL will be generating revenue, could we see these 2 partner at some future date?

User Image valueforme Posted - 4 days ago

$SGMT A lot of people do not understand the importance of having a biomarker that can help to predict / identify defanistat responders based on a simple blood test.

User Image valueforme Posted - 4 days ago

$SGMT The screenshot below is from "Challenges and opportunities in NASH drug development" article written by the Stephen Harrison, MD. He will be leading Sagimet's Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

User Image BondbutnotJames Posted - 6 days ago

$SGMT SGMT will also benefit from this

User Image John___wick44 Posted - 6 days ago

$SGMT back to red again. fraud scam

User Image valueforme Posted - 6 days ago

$SGMT averaged down to 4.03.

User Image kthart Posted - 6 days ago

$SGMT stockconsultant now says triple support at $3.82 (+/- .43) continuing the downward slide like a hot knife through butter.

User Image Stock_Titan Posted - 6 days ago

$SGMT Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024 https://www.stocktitan.net/news/SGMT/sagimet-biosciences-to-host-virtual-investor-and-analyst-day-on-rivuy3zjb2za.html

User Image valueforme Posted - 1 week ago

$SGMT Baker Bros is invited to board meetings

User Image John___wick44 Posted - 1 week ago

$SGMT when is the last green day this pos has had. end of summer all time lows

User Image valueforme Posted - 1 week ago

$SGMT Added below 4

User Image John___wick44 Posted - 1 week ago

$SGMT see u all under 2

User Image valueforme Posted - 1 week ago

$SGMT Interesting https://twitter.com/sagimet/status/1780727394640470287?t=1Wmlz8G-phQHuQ6clxcCWQ&s=19

User Image mmatalon88 Posted - 1 week ago

$SGMT it’s trading as if the drug failed the phase 3 trial even though they didn’t start it

User Image valueforme Posted - 1 week ago

$SGMT Around 165-170M cash on hand as of the end of Q1 2024. A bit more than 30M shares. Traded around 50M below cash with a phase 3 ready NASH asset. Well, this is all you need to know about the current bio market.

User Image maxhappy Posted - 1 week ago

$SGMT Wow, just wow. This stock is beyond pathetic. My rear hurts.

User Image pumperblower Posted - 1 week ago

$SGMT They have an abstract accepted for the EASL June conference.. (abstract number 1326) so probably good news are on the way this should further validate the the drug pipeline.. "1326 Combination of fatty acid synthase (FASN) inhibitor and thyroid hormone receptor beta (THRb) agonist, resmetirom, improved markers of NASH and cardiovascular health in LDL receptor knockout NASH mice Poster presentation Presenter: Wen-Wei Tsai "

User Image maxhappy Posted - 1 week ago

$SGMT Is this just down with other unprofitable biotechs and broken secondaries or is there a nasty bear story out there? The short interest has gone up from 470,000 shares to over 2.35 million shares over the last few months. This is now trading way under cash, which the company said will last them until the end of 2025. The weight loss drugs do not reduce inflammation or cure NASH/MASH despite all the excitement about them for everything. I will keep nibbling all the way down unless the story changes. The shorts will be in for a rough time if this company ever announces anything good.

User Image Effe839 Posted - 1 week ago

$SGMT We are just back at the share price of 1 month ago

User Image BondbutnotJames Posted - 1 week ago

$SGMT new data - some will laugh - some will cry...and I think some will shit their pants - but not out of joy :-)))

User Image John___wick44 Posted - 1 week ago

$SGMT going back to 2 with 10 year going to 5.50

User Image drtwits354 Posted - 1 week ago

$SGMT is this the most manipulated stock ever?

Analyst Ratings
Goldman Sachs Buy Mar 26, 24
Leerink Partners Outperform Mar 25, 24
JMP Securities Market Outperform Feb 7, 24
Goldman Sachs Buy Jan 23, 24
JMP Securities Market Outperform Jan 23, 24
JMP Securities Market Outperform Jan 22, 24
JMP Securities Market Outperform Dec 5, 23
TD Cowen Outperform Aug 8, 23
Piper Sandler Overweight Aug 8, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Happel David President & CEO President & CEO Nov 16 Buy 2.35 590 1,386 590 11/20/23
NEW ENTERPRISE ASSOCIATES 13 L... 10% Owner 10% Owner Jul 18 Sell 16 662 10,592 3,820,275 07/20/23
NEW ENTERPRISE ASSOCIATES 13 L... 10% Owner 10% Owner Jul 18 Buy 16 30,000 480,000 3,850,275 07/20/23